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1. Introduction 
The frequency of lifestyle-related diseases is steadily increasing, particularly of 
hypertension, a risk factor for cardiovascular diseases such as coronary heart disease, 
peripheral arterial disease and stroke. Indeed, cardiovascular diseases are the primary cause 
of morbidity and mortality in Western countries, with hypertension affecting about 20% of 
the world’s adult population [1]. Blood pressure is controlled by various regulatory factors 
in the body, including angiotensin I-converting enzyme (ACE-I). ACE-I 
(peptidyldipeptidaseA, kininase II, EC 3.4.15.1) is a zinc dipeptidylcarboxypeptidase. This 
membrane-bound exopeptidase is found on the plasma membranes of various cell types, 
including vascular endothelial cells, microvillar brush border epithelial cells and 
neuroepithelial cells. It is thought to be physiologically important. The primary activity of 
ACE-I is to cleave broad specificity free carboxyl group oligopeptides. Substrates containing 
Pro at the P1' position and Asp or Glu at P2' are resistant to ACE-I. However, on certain 
substrates ACE-I can also function as an endopeptidase or a tripeptidylcarboxypeptidase. 
With ACE-I, endopeptidase activity is observed on substrates having amidated carboxyl 
groups where the enzyme can cleave a C-terminal dipeptide amide and/or a C-terminal 
tripeptide amide [2]. ACE-I is responsible for converting angiotensin I (Ang I) to the 
powerful vasoconstrictor angiotensin II (Ang II) and inactivating the vasodilator peptide 
bradykinin (BK) by removal of C-terminal dipeptides [3]. In a functional sense, therefore, the 
enzymatic actions of ACE-I potentially cause increased vasoconstriction and decreased 
vasodilation. ACE-I has attracted interest for development of orally-active ACE-I inhibitors 
to treat hypertension due to its central role in vasoactive peptide metabolism. Inhibition of 
ACE-I prevents conversion of Ang I into Ang II, making it becomes one of the most effective 
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methods for suppressing increases in blood pressure [4]. Since discovery of ACE-I inhibitors 
in snake venom, extensive research has been done on synthesizing ACE-I inhibitors such as 
captopril, enalapril, alacepril and lisinopril, all currently in use for treatment of 
hypertension and heart failure in humans. However, these synthetic drugs occasionally 
produce side effects such as cough, taste alterations and skin rashes. Interest has 
consequently increased in natural ACE-I inhibitors as safer and lower cost alternatives to 
synthetic ones [5]. 
Antioxidant deficiency also has been implicated in the occurrence of hypertension and other 
degenerative diseases. Reactive oxygen species (ROS) such as the superoxide anion radical 
(O-2), hydrogen peroxide and hydroxyl radicals (●OH) are physiological metabolites formed 
as result of respiration in aerobic organisms. ROS are very unstable, and react rapidly with 
other substances including DNA, membrane lipids and proteins. Oxidative stress is 
produced by an imbalance between oxidizing species and natural antioxidants in the body, 
and has been associated with aging, cell apoptosis and severe diseases such as cancer, 
Parkinson, Alzheimer, and cardiovascular disorders [6]. Epidemiological studies have 
demonstrated an inverse association among intake of antioxidants from fruits and 
vegetables, and morbidity and mortality due to coronary heart diseases and cancer. In 
response, researchers are searching for natural antioxidants in food that may protect the 
body from free radicals and retard the evolution of many chronic diseases [7].  
In recent years, food proteins have gained increasing value due to the rapidly expanding 
knowledge about physiologically active peptides. Peptides from various dietary sources 
have been shown to have clearly positive effects on health by functioning as 
antihypertensives, antioxidants, anticarcinogens, antimicrobials and anticariogenics, among 
others. These properties have led to their labeling as functional or biologically-active (i.e. 
bioactive) peptides. Bioactive peptides may be encrypted within the amino acid sequence of 
a larger protein. These peptides usually consist of 3-20 amino acids and are released from 
the original protein after degradation [8]. The most common way to produce bioactive 
peptides is through enzymatic hydrolysis of whole protein molecules. After enzymatic 
processing, amino acid sequences that were inactive in the core of the source protein are 
released and can exercise special properties. Many of the known bioactive peptides have 
been produced using gastrointestinal enzymes, usually pepsin and trypsin. Other digestive 
enzymes and different enzyme combinations of proteinases-including Alcalase®, 
chymotrypsin, pancreatin, pepsin and thermolysin have also been utilized to generate 
bioactive peptides from various proteins [9].  
Continued population growth worldwide, consequent food resource shortages in 
developing countries, and the health risks associated with excessive animal protein (and 
saturated fats) intake has led researchers to search for new sources of proteins from non-
conventional raw materials. Legumes are cultivated worldwide and constitute an excellent 
protein source (protein content =20-30%). Cowpea (Vigna unguiculata) is a major legume crop 
worldwide, particularly in tropical and subtropical areas such as southeast Mexico. It serves 
as a major dietary protein source in both human and animal diets, and its protein content 
makes it a good raw material for preparation of protein extracts and hydrolysates. Protein 
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extract has been used as substrates for production of hydrolysates with functional and/or 
nutritional properties better than the original extract [10]. Bioactive peptides with ACE-I 
inhibitory activity has been isolated from protein hydrolysates from a number of animal and 
vegetable sources. Vegetable origin proteins are of particular interest, and legumes are 
especially promising due to their high protein content and diverse physiological activities in 
the human organism. Extensive hydrolysis of V. unguiculata protein concentrates with 
commercial and digestives enzymes could therefore produce a number of peptides with a 
myriad of potential applications; for example, as natural-source therapeutic agents in 
medical treatments and/or as an ingredient in functional foods. Taking this into account, the 
aim of the present study was to modify enzymatically protein concentrates of V. unguiculata, 
evaluate the ACE-I inhibitory and antioxidant potential of the hydrolysates and relate the 
biological activity to their amino acid compositions.  
2. Material and methods  
2.1. Materials 
V. unguiculata seeds were obtained from the February 2007 harvest in Yucatan state, Mexico. 
Reagents were of analytical grade and purchased from J.T. Baker (Phillipsburg, NJ, USA), 
Sigma Chemical Co. (St. Louis, MO, USA), Merck (Darmstadt, Germany) and Bio-Rad 
Laboratories, Inc. (Hercules, CA, USA). Alcalase® 2.4L FG and Flavourzyme® 500MG 
enzymes were purchased from Novo Laboratories (Copenhagen, Denmark). 
2.2. Protein isolates 
A single extraction was performed with 6 kg of cowpea seeds. Impurities and damaged seeds 
were removed, and sound seeds milled in a Mykros impact mill (Industrial Machinery, 
Monterrey, Mexico) until passing through a 20-mesh screen (0.85 mm) followed by milling in a 
Cyclotec 1093 (Tecator, Sweden) mill until passing through a 60-mesh screen (0.24 mm). The 
resulting flour was processed using the wet fractionation method of Betancur-Ancona [11]. 
Briefly, whole flour was suspended in distilled water at a 1:6 (w/v) ratio, pH was adjusted to 
11.0 with 1 M NaOH, and the dispersion was stirred for 1 h at 0.178 x g with a mechanical 
agitator (Caframo Rz-1, Heidolph Schwabach, Germany). This suspension was wet-milled 
with a Kitchen-Aid® food processor, and the fiber solids were separated from the starch and 
protein mix by straining through 80- and 150-mesh sieves and washing the residue five times 
with distilled water. The protein-starch suspension was allowed to sediment for 30 min at 
room temperature to recover the starch and protein fractions. The pH of the separated 
solubilized proteins was adjusted to the isoelectric point (4.5) with 1 N HCl. The suspension 
was then centrifuged at 1317 x g for 12 min (Mistral 3000i, Curtin Matheson Sci.), the 
supernatants were discarded, and the precipitates were freeze-dried until use. 
2.3. Enzymatic hydrolysis 
Hydrolysis of the protein extract was done using a totally randomized design with the 
treatments being the enzymatic system applied: Alcalase® 2.4L FG; Flavourzyme® 500MG; or 
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a sequential system using pepsin from porcine gastric mucosa (Sigma, P7000-100G) and 
pancreatin from porcine pancreas (Sigma, P3292-100G). The response variable was degree of 
hydrolysis (DH). 
Hydrolysis was done under controlled conditions (temperature, pH and stirring) in a 1000 
mL reaction vessel equipped with a stirrer, thermometer and a pH electrode. Hydrolysis 
with Alcalase® and Flavourzyme® was done according to Pedroche et al. [12]. Protein 
extracts were suspended in distilled water to produce a 4% (w/v) protein solution. This 
solution was equilibrated at optimum temperature and pH for each protease before adding 
the respective enzyme. Protease was then added to the solution at a ratio of 0.3 UA/g for 
Alcalase® and 50 UAPL/g for Flavourzyme®. Hydrolysis conditions were 90 min at 50°C for 
both enzymes, and pH 8.0 for Alcalase® and pH 7.0 for Flavourzyme®. The pH was kept 
constant by adding 1.0 M NaOH during hydrolysis. Hydrolysis with the sequential pepsin-
pancreatin system was done with a pH-stat method for 90 min: pre-digestion with pepsin 
for 45 min followed by incubation with pancreatin for 45 min. Hydrolysis parameters were 
substrate concentration 4%; enzyme/substrate ratio 1:10; pH 2 for pepsin; pH 7.5 for 
pancreatin; and 37°C [13, 14]. In all three treatments the reaction was stopped by heating to 
80°C for 20 min, followed by centrifugation at 9,880 x g for 20 min to remove the insoluble 
portion. 
2.4. Degree of hydrolysis 
DH was calculated by calculating free amino groups with o-phthaldialdehyde [15]: DH= 
h/htot *100, where htot is the total number of peptide bonds per protein equivalent, and h is 
the number of hydrolyzed bonds. The htot factor is dependent on raw material amino acid 
composition.  
2.5. Hydrolysate fractionation by ultrafiltration 
Following Cho et al. [16], the hydrolysate was fractionated by ultrafiltration using a high 
performance ultrafiltration cell (Model 2000, Millipore, Inc., Marlborough, MA, USA). Five 
fractions were prepared using four molecular weight cut-off membranes: 1 kDa, 3 kDa, 5 
kDa and 10 kDa. Soluble fractions prepared by centrifugation were passed through the 
membranes stating with the largest Molecular Weight Cut off (MWCO) membrane cartridge 
(10 kDa). The retentate and permeate were collected separately, and the retentate 
recirculated into the feed until maximum permeate yield was reached, as indicated by a 
decreased permeate flow rate. The permeate from the 10 kDa membrane was then filtered 
through the 5 kDa membrane with recirculation until maximum permeate yield was 
reached. The 5 kDa permeate was then processed with the 3 kDa membrane and the 3 kDa 
permeate with the 1 kDa membrane. This process minimized contamination of the larger 
molecular weight fractions with smaller molecular weight fractions while producing enough 
retentates and permeates for the following analyses. The five ultrafiltered peptide fractions 
were designated as >10 kDa (10 kDa retentate); 5-10 kDa (10 kDa permeate-5 kDa retentate); 
3-5 kDa (5 kDa permeate- 3 kDa retentate); 1-3 kDa (3 kDa permeate-1 kDa retentate); and <1 
kDa (1 kDa permeate).  
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2.6. ACE-I inhibitory activity 
ACE-I inhibitory activity in the hydrolysate and its purified peptide fractions was analyzed 
following Hayakari et al. [17]. ACE-I hydrolyzes hippuryl-L-histidyl-L-leucine (HHL) to 
yield hippuric acid and His-Leu. This method relies on the colorimetric reaction of hippuric 
acid with 2,4,6-trichloro-s-triazine (TT) in a 0.5 mL incubation mixture containing 40 μmol 
potassium phosphate buffer (pH 8.3), 300 μmol sodium chloride, 40 μmol 3% HHL in 
potassium phosphate buffer (pH 8.3) and 100 mU/mL ACE-I. The mixture was incubated at 
37ºC for 45 min and then reaction terminated by addition of TT (3% v/v) in dioxane and 3 ml 
of 0.2 M potassium phosphate buffer (pH 8.3). After centrifuging the reaction mixture at 
10,000 x g for 10 min, enzymatic activity was determined in the supernatant by measuring 
absorbance at 382 nm. All runs were performed in triplicate. ACE-I inhibitory activity was 
quantified by a regression analysis of ACE-I inhibitory activity (%) versus peptide 
concentration and defined as an IC50 value, that is, the peptide concentration in (μg 
protein/mL) required to produce 50% ACE-I inhibition under the described conditions.  
2.7. Antioxidant activity by ABTS assay 
2,2’azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical cation (ABTS●+) was 
produced by reacting ABTS with potassium persulfate following Pukalskas et al. [18]. To 
prepare the stock solution, ABTS was dissolved at a 2 mM concentration in 50 mL phosphate-
buffered saline (PBS) prepared from 4.0908 g NaCl, 0.1347 g KH2PO4, 0.7098 g Na2HPO4, and 
0.0749 g KCl dissolved in 500 mL ultrapure water. If pH was lower than 7.4, it was adjusted 
with NaOH. A 70 mM K2S4O8 solution in ultrapure water was prepared. ABTS●+ radical was 
produced by reacting 10 mL of ABTS stock solution with 40 L K2S4O8 solution and allowing 
the mixture to stand in darkness at room temperature for 16-17 h before use. The radical was 
stable in this form for more than 2 days when stored in darkness at room temperature. 
Antioxidant compound content in the hydrolysates and their UF peptide fractions was 
analyzed by diluting the ABTS●+ solution with PBS to an absorbance of 0.800 ± 0.030 AU at 
734 nm. After adding 990 L of diluted ABTS●+ solution (A734 nm= 0.800 ± 0.030) to 10 L 
antioxidant compound or Trolox standard (final concentration 0.5-3.5 mM) in PBS, 
absorbance was read at ambient temperature exactly 6 min after initial mixing. All analyses 
were run in triplicate. The percentage decrease in absorbance at 734 nm was calculated and 
plotted as a function of the concentration of Trolox for the standard reference data. The 
radical scavenging activity of the tasted samples, expressed as inhibition percentage, was 
calculated by the following formula: 
% Inhibition= [(AB-AA)/AB] x 100 
Where AB was the absorbance of the blank sample (t=0), and AA was the absorbance of 
sample with antioxidant after 6 min. 
Trolox equivalent antioxidant coefficient (TEAC) was quantified by a regression analysis of 
% Inhibition versus Trolox concentration using the following formula: 
TEAC = (%IM – b)/m 
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Where b was the intersection and m was the slope.  
2.8. G-50 gel filtration chromatography 
After filtration through 10, 5, 3 and 1 kDa membranes in a high performance ultrafiltration 
cell, 10 mL of the fraction with highest ACE-I inhibitory activity was injected into a 
Sephadex G-50 gel filtration column (3 cm x 79 cm) at a flow rate of 25 mL/h of 50 mM 
ammonium bicarbonate (pH 9.1). The resulting fractions were collected for to assay ACE-I 
inhibitory activity. Peptide molecular masses were determined by reference to a calibration 
curve created by running molecular mass markers on the Sephadex G-50 under conditions 
identical to those used for the test samples. Molecular mass standards were thyroglobulin 
(670 kDa), bovine gamma globulin (158 kDa), equine myoglobin (17 kDa), vitamin B12 (1.35 
kDa) and Thr-Gln (0.25 kDa). Fractions selected for further purification of peptides were 
pooled and lyophilized before RP-HPLC.  
2.9. HPLC C18 chromatography  
The fractions isolated with the Sephadex G-50 column were redissolved in deionized water 
and injected into a preparative HPLC (Agilent, Model 1110, Agilent Technologies, Inc. Santa 
Clara, CA, USA) reverse-phasecolumn (C18 Hi-Pore RP-318, 250 mm x10 mm, Bio-Rad). The 
injection volume was 100 L, and the sample concentration was 20 mg/mL. Elution was 
achieved by a linear gradient of acetonitrile in water (0-30% in 50 min) containing 0.1% 
trifluoroacetic acid at a flow rate of 4 mL/min and 30°C [13]. Elution was monitored at 215 
nm, and the resulting fractions were collected for assay of ACE-I inhibitory activity as 
described above. 
2.10. Amino acid composition  
Protein amino acid composition was determined for the hydrolysate, and the peptides were 
purified by ultrafiltration, gel filtration chromatography and HPLC [19]. Samples (2-4 mg 
protein) were treated with 4 mL of 6 mol equi/L HCl, placed in hydrolysis tubes and gassed 
with nitrogen at 110°C for 24 h. They were then dried in a rotavapor and suspended in 1 
mol/L sodium borate buffer at pH 9.0. Amino acid derivatization was performed at 50°C 
using diethyl ethoxymethylenemalonate. Amino acids were separated using HPLC with a 
reversed-phase column (300 x 3.9 mm, Nova Pack C18, 4 mm; Waters), and a binary 
gradient system with 25 mmol/L sodium acetate containing (A) 0.02 g/L sodium azide at pH 
6.0, and (B) acetonitrile as solvent. The flow rate was 0.9 mL/min, and the elution gradient 
was: time 0.0–3.0 min, linear gradient A:B (91:9) to A-B (86:14); time 3.0–13.0 min, elution 
with A-B (86–14); time 13.0–30.0 min, linear gradient A-B (86:14) to A-B (69:31); time 30.0–
35.0 min, elution with A-B (69:31). 
2.11. Statistical analysis 
All results were analyzed in triplicate using descriptive statistics with a central tendency 
and dispersion measures. One-way ANOVAs were performed to evaluate protein isolate 
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hydrolysis data and in vitro ACE-I inhibitory activity. A Duncan’s multiple range test was 
used to determine differences between treatments. All analyses were performed according 
to Montgomery [20] and processed using the Statgraphics Plus version 5.1 software. 
3. Results and discussion 
3.1. Protein extract hydrolysis 
Alcalase®, Flavourzyme® and pepsin-pancreatin were used to produce extensively 
hydrolyzed V. unguiculata protein extracts. Degree of hydrolysis (DH) differed (P<0.05) 
between the enzymatic systems with values of 53.0%, 58.8%, and 35.7% for Alcalase® 
hydrolysate (AH), Flavourzyme® hydrolysate (FH) and Pepsin-pancreatin hydrolysate 
(PPH), respectively. 
The AH had a 53.0% DH, which is lower than reported by Vioque et al. [21] for rapeseed 
protein hydrolysates (60% DH) produced with a mixture of Alcalase® and Flavourzyme® 
during 180 min. However, this DH was higher than that reported for mung bean protein 
hydrolysates (20.0% DH) produced with Alcalase® for 10 h[22] and for V. unguiculata 
hydrolysates (32.3% DH) produced with Alcalase® for 60 min [10].The variation in DH 
observed here is probably the result of protease specificity since Alcalase® is an industrial 
alkaline protease produced from Bacillus licheniformis, the main enzyme component of which 
(serine endopeptidase subtilisin Carlsberg) presents broad specificity and hydrolyzes most 
peptide bonds, with a preference for those containing aromatic amino acid residues [23]. 
ACE-I prefers substrates or competitive inhibitors containing hydrophobic amino acid 
(aromatic or branched lateral chain) residues (Hong et al., 2005). Alcalase® is therefore very 
suitable for production of bioactive peptides, such as those with ACE-I inhibitory activity. 
According to Pedroche et al. [24] the controlled liberation of biologically active peptides 
from protein by enzymatic hydrolysis is one of the most promising trends concerning 
medical applications of the protein hydrolysates with DH higher than 10% while 
hydrolysates with a low DH (lower than 10%) are used for the improvement of functional 
properties of flours or protein isolates. Therefore, the results suggest (DH=53.0%) that V. 
unguiculata protein is an appropriate substrate for producing these bioactive peptides when 
hydrolyzed with Alcalase®. 
Hydrolysis with Flavourzyme® produced a V. unguiculata hydrolysate with 58.8% DH, 
somewhat higher than obtained with the Alcalase® system. A similar discrepancy has been 
reported for chickpea protein hydrolysates (27.0% DH) produced with Flavourzyme® for 
180 min [25]. DH was higher with Flavourzyme® since it is a protease complex produced by 
Aspergillus orizae, which contains endoproteinases and exopeptidases. The fungal protease 
complex Flavourzyme® has a broader specificity; thus, when combined with its 
exopeptidase activity high DH values can be achieved, perhaps as much as 50% giving 
mostly dipeptides in the hydrolysate. 
Sequential hydrolysis with pepsin-pancreatin produced cowpea protein hydrolysates with 
the lowest DH (35.74%) of the three studied enzymatic systems. This DH was similar to 
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37.0% at 360 min reported for sunflower protein hydrolysates obtained with the same 
system [13], but higher than the reported values for soy protein hydrolysates produced with 
pancreatin for 60 (11.0%) and 180 min (17.0%) [26]. The V. unguiculata PPH represents a pool 
of peptides resembling those generated during digestion of V. unguiculata proteins in the 
organism. This coincides with the behavior of extensively hydrolyzed sunflower protein 
reported by Megías et al. [13].Pepsin is the main proteolytic enzyme generated in the 
stomach during food digestion, while pancreatin includes proteases such as trypsin, 
chymotrypsin and elastase, which are released by the pancreas in the small intestine. The 
resulting peptides are therefore resistant to pepsin and pancreatin, suggesting that they 
might be absorbed by digestive epithelial cells in the small intestine, probably might be 
bioavailable and exercise their biological activity. 
3.2. ACE-I inhibitory activity 
ACE-I inhibitory activity of AH, FH and PPH was measured and calculated as IC50. 
Biological activity was highest in the PPH, as indicated by a lower IC50 value (1397.9 g/ml) 
compared to the AH (2564.7 g/ml) and FH (2634.4 g/ml). In other words, more ACE-I 
inhibitory active peptides were produced using the pepsin-pancreatin treatment. 
ACE-I inhibitory activity has been reported for enzymatic hydrolysates from different 
protein sources with IC50 values ranging from 0.2 to 246.7 g/mL [22]. Many of these 
hydrolysates have been shown to have antihypertensive activities in spontaneously 
hypertensive rats (SHR). In the present study, the IC50 value for the hydrolysate prepared 
with pepsin-pancreatin at 90 min incubation is within the concentration range likely to 
mediate an antihypertensive effect. Therefore, it is to be expected that V. unguiculata protein 
derived ACE-I inhibitory peptides would have antihypertensive activity. However, further 
investigations are necessary to examine whether the peptide mixture may exert 
antihypertensive activity in vivo because the inhibitory potencies of the peptides on ACE-I 
activity do not always correlate with their antihypertensive activities found in SHR[22].  
Ultrafiltration of AH, FH and PPH produced peptide fractions with increased biological 
activity (Fig. 1). ACE-I inhibitory activity of peptide fractions ranged from 24.3-123 g/ml in 
the AH, from 0.04 to 170.6 g/ml in the FH and from 44.7 to 112 g/ml in the PPH. ACE-I 
inhibitory activity was significantly (P<0.05) dependent on peptide fraction molecular 
weight, with the lowest activity being in the >10kDa fractions and the highest in the <1kDa 
fractions for all hydrolysates. Similar ACE-I inhibitory activity behavior was reported by Je 
et al.[5]for five peptide fractions from pepsin-hydrolyzed Alaska pollack frame protein run 
through an ultrafiltration membrane-bioreactor system with MWCOs of 30, 10, 5, 3 and 1 
kDa. Higher ACE-I inhibitory activity (%) in lower molecular weight fractions was also 
reported by Xue-Ying et al. [27] for yak casein hydrolysate fractions separated using 6 and 
10 kDa MWCOs: >10kDa (23.1%), 6-10kDa (29.2%) and <6 kDa (85.4%).  
Of the three hydrolysates tested in the present study, FH, which had the highest DH, also 
exhibited the highest ACE-I inhibitory activity in the <1kDa fraction. The biological activity 
of this fraction provides it potential commercial applications as a ‘health-enhancing 
ingredient’ in functional food production. 
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In terms of ACE-I inhibitory activity, the pepsin-pancreatin system produced hydrolysate 
with the highest activity, while the Flavourzyme® system produced peptide fractions with 
the highest activity. This also confirms that V. unguiculata is a good protein source for 
bioactive peptide extraction by gastrointestinal or commercial proteases. 
 
Figure 1. IC50 values of peptide fractions obtained by ultrafiltration from V. unguiculata protein 
hydrolysates. 
3.3. Antioxidant activity by ABTS assay 
Antioxidant activity of the protein hydrolysates and their corresponding UF peptide 
fractions was quantified and calculated as TEAC values (mM/mg protein). Antioxidant 
activity was not significantly different (P>0.05) between the three hydrolysis systems (14.7 
for AH, 14.5 for FH and 14.3 mM/mg protein for PPH). Ultrafiltration improved antioxidant 
activity, which was dependent (P<0.05) on fraction molecular weight (Fig. 2).TEAC values 
were 303.2-1457 mM/mg protein for the AH, 357.4-10211 mM/mg protein for the FH, and 
267.1-2830.4 mM/mg protein for the PPH. These values, and consequently the fraction’s 
antioxidant activities, were higher (P<0.05) as fraction molecular weight decreased. 
According to Dávalos et al. [28] this behavior among the V. unguiculata peptide fractions 
may reflect the enhanced accessibility of small peptides to the redox reaction system, for the 
prescence of critical amino acid residues. 
Antioxidant activity in the V. unguiculata protein hydrolysates and their UF peptide 
fractions was measured with an ABTS assay, which quantifies an antioxidant’s (i.e. 
hydrogen or electron donor) suppression of the radical cation ABTS●+ based on single-
electron reduction of the relatively stable radical cation ABTS●+ formed previously by an 
oxidation reaction. When added to PBS medium (pH 7.2) containing ABTS●+, the proteins in 
the hydrolysates and peptide fractions very probably acted as electron donors, transforming 
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this radical cation (maximum absorbance at 734nm) into the non-radical ABTS. The higher 
antioxidant activity of the UF peptide fractions versus their source hydrolysates is related to 
unique properties provided by their amino acid composition. The fractions’ increased ability 
to decrease free radical reactivity is linked to the greater exposure of their amino acids, 
which leads to increased peptide/free radical reactions. 
 
Figure 2. Antioxidant activity of peptide fractions obtained by ultrafiltration from V. unguiculata 
protein hydrolysates. 
Overall, the <1 kDa peptide fraction from the FH had the highest TEAC values and was 
shown to undergo single-electron transfer reactions in the ABTS●+ reduction assay, 
demonstrating its antioxidant capacity. This is an extremely attractive property since 
oxidants are known to be involved in many human diseases and aging processes. Oxidants 
are associated with the chronic damage of ageing, and destructive oxidants and oxygen-free 
radicals can be extremely toxic to tissues by promoting tissue necrosis and cell damage. 
Some authors claim that proteins possess antioxidant properties; for instance, [29] reported 
that protein insufficiency aggravates enhanced lipid peroxidation and reduces antioxidative 
enzyme activities in rats, while Larson et al. [30] observed that proteins affect lipid 
metabolism in laboratory animals. The biological effect exhibited by the FH<1kDa fraction 
apparently reinforces the claim that proteins possess antioxidant properties. This makes the 
FH<1kDa fraction a potential “antioxidant” ingredient in functional food production.  
3.4. Gel filtration chromatography 
Because it exhibited the highest ACE-I inhibitory (IC50 value of 0.04 g/mL) and antioxidant 
activity (TEAC value of 10211 mM/mg protein), the <1 kDa fraction from FH was selected 
for further fractionation. Gel filtration chromatography was used to generate a molecular 
weight profile of this fraction (Fig. 3).  
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Figure 3. Elution profile of the <1 kDa ultrafiltration fraction of the cowpea V. unguiculata protein 
hydrolysate with Flavorzyme® purified in a Sephadex G-50 gel filtration column.  
The profile was typical of a protein hydrolysate formed by a pool of peptides, with 
gradually decreasing molecular masses. Elution volumes between 406 and 518 mL included 
free amino acids and peptides with molecular masses ranging from 3.6 to 0.4 kDa. This 
range was fractionated into eleven fractions (1 to 11) and ACE-I inhibitory activity 
determined for each. Fractions with elution volumes smaller than 406 mL and greater than 
518 mL were not analyzed because they largely included peptides with high molecular 
weights, as well as free amino acids. ACE-I inhibitory activity (%) in the eleven fractions 
ranged from 5.29 to 47.43% and differed (P<0.05) between fractions (Table 1). The highest 
ACE-I inhibitory activity was observed in fractions F4 (47.43%; 437.5-444.5 mL elution 
volume) and F5 (45.14%, 448-455 mL elution volume), which were not statistically different 
(P<0.05). Their molecular masses were approximately 1.8 kDa (indicative of 7 amino acid 
residues) and 1.5 kDa (indicative of 10 amino acid residues), respectively. The IC50 value for 
F4 (14.19 g/mL) was similar than those of Fagopirum esculentum peptide fractions purified 
by Sephadex LH-20 gel filtration (15.1 g/mL) [31], but lower than those of gel filtration 
(Sephadex G-25) peptide fractions from tuna broth hydrolysate (210 to 25,260 g/mL) [32], 
from Fagopyrum esculentum Moench (Sephadex C-25 = 25,715.1 g/mL; Sephadex G-10 = 
21,315.1 g/mL), and from the peptic hydrolysate of Acetes chinensis (Sephadex C-15 = 770 – 
1590 g/mL) [33]. A similar behavior pattern was observed with Konjac peptides purified by 
series connection of Sephadex G-25 and Sephadex G-15 columns that resulted in purified 
peptides with molecular weights of 1500 and 1000 Da and IC50 values of 120 g/mL and 88 
g/mL, respectively [34]. Ji-Eun et al. [35] reported similar results to separate peptide 
fractions below 3 kDa through size exclusion chromatography (IC50= 500 g/mL) from 
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textured and fermented vegetable protein (IC50 = 2190 g/mL). They purified peptide 
fraction with a molecular weight range of 500-999 Da with IC50 values of 94 g/mL and that 
represented peptides of approximately 7 amino acids residues. 
 
Fraction 
ACE-I inhibitory 
activity (%) 
Fraction 
ACE-I inhibitory 
activity (%) 
F1 28.47C F7 37.61d 
F2 10.67a F8 29.9c 
F3 25.61bc F9 22.01b 
F4 47.43e F10 20.92b 
F5 45.14e 
F11 5.29a 
F6 37.58d 
Table 1. ACE-I inhibition percentage of peptide fractions purified in a Sephadex G-50 gel filtration 
column.a-eDifferent superscripts letters indicate statistical difference (P <0.05). Data are the mean of 
three replicates. 
3.5. Reverse-phase HPLC chromatography of pooled fractions 
Fractions F4 and F5 from the gel filtration chromatography treatment were pooled and 
analyzed using RP-HPLC to produce a chromatographic profile from mass-transfer between 
stationary and mobile phases. Mixture components were separated by dissolving fractions 
F4 and F5 in acetonitrile and forcing them through a chromatographic column under high 
pressure. The mixture resolved into its components in the column, separating F4 and F5 
based on differences in hydrophobicity. In this process, the components of both fractions 
passed over stationary-phase particles containing pores large enough for them to enter, and 
in which interactions with the hydrophobic surface removed them from the flowing mobile-
phase stream. The strength and nature of the interaction between the sample particles and 
stationary phase depended on hydrophobic and polar interactions. As the eluent organic 
solvent concentration increased, it reached a critical value for each analyte and desorbed it 
from the hydrophobic stationary-phase surface to allowing it to elute from the column into 
the flowing mobile phase. Because this elution depended on the precise distribution of 
hydrophobic residues in each specie, each analyte eluted from the column at a characteristic 
time and the resulting peaks were used to qualitatively analyze both fractions’ components. 
Within each gel filtration fraction, the eluates were divided into four major fractions: F4-1, 
F4-2, F4-3, F4-4; F5-1, F5-2, F5-3, F5-4. The peptides were relatively pure, although a small 
shoulder still appeared behind the peaks in the chromatogram. 
Enough material from each fraction was collected in successive analyses to determine ACE-I 
inhibitory activity (Fig. 4). Fraction F4 had a larger (P<0.05) ACE-I inhibitory activity range 
(33.83 to 75.42%) than F5 (32.31 to 49.71%). Overall, F4-2 (75.42%) had the highest ACE-I 
inhibitory activity (IC50 = 0.4704 g/mL). This value is lower than the 6.3 g/ml reported for a 
peptide from F. esculentum Moench purified by RP-HPLC [31] and within the 8.1 to 91.6 
g/mL range reported for fractions from caprine kefir water-soluble extract purified by 
preparative RP-HPLC [36]. The same behavior was observed when comparing the results of 
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RP-HPLC fractions obtained of Mustelus mustelus intestines with alkaline proteases (130- 783 
g/ml) [37] and with peptide fractions obtained from the peptic hydrolysate of the 
freshwater rotifer Brachionus calyciflonus (40.01 g/ml) [38]. 
 
Figure 4. ACE inhibition percentage of RP-HPLC fractions obtained from fractions F4 and F5 produced 
after hydrolysis of V. unguiculata with Flavourzyme®.a-cDifferent letters in the same gel filtration 
chromatography fraction indicate statistical difference (P<0.05). Data are the mean of three replicates. 
3.6. Amino acid composition  
Fractions with the highest ACE-I inhibitory activity were analyzed to produce an amino acid 
profile. During hydrolysis, asparagine and glutamine partially converted to aspartic acid 
and glutamic acid, respectively; the data for asparagine and/or aspartic acid were therefore 
reported as Asx while those for glutamine and/or glutamic acid were reported as Glx. The 
higher ACE-I inhibitory activity exhibited by the <1 kDa fraction (IC50=0.04 g/mL) 
compared to FH (IC50=2634.4 g/mL) was probably due to its higher concentration of neutral 
amino acids, such as Ser (3.03%) and Thr (11.36%), hydrophilics such as His (12.5%) or 
hydrophobics such as Ala (7.84%), Pro (23.80%), Val (10%), Met (66.66%), Ile (10%), Leu 
(21.6%), Phe (18.6%) and Trp (16.6%) (Table 2). 
Compared to the <1 kDa fraction amino acid profile, the G-50 gel filtration chromatography 
fractions had higher Asx, Glx and Arg concentrations. Hydrophobic amino acid content 
decreased by 20.27% in F4 (34.56g/100g) and 21.19% in F5 (34.16g/100g) compared to the <1 
kDa fraction (43.35 g/100g), while hydrophilic residues increased by 19.25% (48 g/100g) in F4 
and 22.48% (50 g/100g) in F5. The ACE-I inhibitory activity observed in F4 (47.43%) and F5 
(45.14%) could therefore be the result of their higher Arg, Asx or Asp concentrations. These 
residues are known to play an important role in the antihypertensive activity of peptides 
from white and red wines and from French flor-sherry wine [38]. The F4 and F5 fractions 
may also have the added benefit of low bitterness. Many of the ACE-I-inhibitory peptides 
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isolated from food sources are composed of multiple food components and hydrophobic 
and/or aromatic amino acid residues. However, practical use of these food protein 
hydrolysates is complicated by formation of peptides, which impart a bitter taste, the result 
of the formation of low molecular weight peptides containing mostly hydrophobic amino 
acids. To address this problem, Kim et al. [40] recommended use of Flavourzyme®, a fungal 
endoprotease and exo-protease complex that produces hydrolysates or peptides with ACE-I 
inhibitory activity and low bitterness. Fractions F4 and F5 are promising prospects for use in 
new product development because they had clear ACE-I inhibitory activity and low 
hydrophobic amino acid content, which may ensure that they have low bitterness. 
 
Amino acid 
Composition (g/100g)* 
PC FH F<1 kDa F4 F5 
Asx 10.8 ± 0.003 9.6 ± 0.387 9.4 ± 0.448 14 ± 0.274 16.7 ± 0.152 
Glx 19 ± 0.016 18.6 ± 0.013 14.9 ± 0.171 17.9 ± 0.182 18.3 ± 0.17 
Ser 6.5 ± 0.041 6.4 ± 0.016 6.6 ± 0.046 5.8 ± 0.302 5.0 ± 0.126 
His 2.9 ± 0.028 2.8 ± 0.001 3.2 ± 0.024 2.9 ± 0.008 2.7 ± 0.061 
Gly 4.4 ± 0.005 4.5 ± 0.006 4.1 ± 0.035 4.3 ± 0.011 3.0 ± 0.177 
Thr 4.3 ± 0.009 3.9 ± 0.009 4.4 ± 0.032 4.0 ± 0.040 3.4 ± 0.036 
Arg 7.8 ± 0.067 7.9 ± 0.025 6.0 ± 0.073 7.5 ± 0.026 6.9 ± 0.039 
Ala 4.4 ± 0.008 4.7 ± 0.002 5.1 ± 0.106 4.3 ± 0.016 3.6 ± 0.625 
Pro 2.7 ± 0.078 1.6 ± 0.038 2.1 ± 0.01 0 ± 0 0 ± 0 
Tyr 2.6 ± 0.098 2.7 ± 0.006 2.6 ± 0.026 2.2 ± 0.018 1.2 ± 0.078 
Val 5.4 ± 0.052 6.3 ± 0.015 7.0 ± 0.029 5.3 ± 0.004 4.2 ± 0.211 
Met 0.1 ± 0.109 0.3 ± 0.001 0.9 ± 0.013 0.7 ± 0.006 2.2 ± 0.292 
Cys 0.4 ± 0.002 0.4 ± 0.006 0.2 ± 0.002 1.2 ± 0.01 3.2 ± 0.1 
Ile 4.4 ± 0.019 5.4 ± 0.207 6.0 ± 0.073 5.2 ± 0.015 4.7 ± 0.236 
Leu 9.2 ± 0.115 9.8 ± 0.175 12.5 ± 0.029 11.6 ± 0.092 12.6 ± 0.229 
Phe 6.9 ± 0.008 7.0 ± 0.004 8.6 ± 0.056 6.7 ± 0.046 5.8 ± 0.043 
Lys 7.3 ± 0.089 7.1 ± 0 5.3 ± 0.072 5.7 ± 0.042 5.3 ± 0.263 
Trp 0.7 ± 0.064 1.0 ± 0.038 1.2 ± 0.041 0.8 ± 0.241 1.0 ± 0.535 
*Data are the mean of three replicates 
Table 2. Amino acid contents of the cowpea V. unguiculata protein concentrate (PC), Flavourzyme 
hydrolysate (FH), <1 kDa ultrafiltered fraction and F4 and F5 gel filtration chromatography fractions. 
Comparison of amino acid composition and properties between the cowpea V. unguiculata 
hydrolysate and its peptides isolated by ultrafiltration and G-50 gel chromatography 
showed the most active fraction to be the <1 kDa fraction, which had abundant aromatic 
(e.g., Phe) and cyclic amino acids (e.g., Pro). Amino acids such as Phe, with large bulky 
chains and hydrophobic side chains, are preferred in both positions of a dipeptide for their 
high steric properties and low lipophilicity, while amino acids such as Pro are preferred in 
the carboxyl terminus of active tripeptides for their low lipophilicity, and high steric and 
electronic properties [41]. Aromatic and basic amino acids are important to the ACE-I 
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inhibitory activity of peptides. For instance, similar observations have been made for an 
orientase hydrolysate with notable ACE-I inhibition attributed to its high basic and aromatic 
amino acids contents [33]. Cheung et al. [43] reported a peptide with strong, competitive 
ACE-I inhibition in which aromatic amino acid residues at its C-terminal and basic or 
hydrophobic ones at its N-terminal played an essential role. Based on the above, the higher 
ACE-I inhibitory potential of the <1 kDa fraction from the cowpea hydrolysate can be 
attributed to the steric properties of its aromatic amino acids and the lipophilicity and 
electronic properties of its cyclic amino acids. 
The most active fraction among those purified from F4 by preparative RP-HPLC was F4-2, 
which had much higher neutral amino acid content (80.6 g/100g) than F4-1 (46.6 g/100g), F4-
3(6.1 g/100g) and F4-4 (28.6 g/100g) (Table 3). Of the neutral amino acids, Tyr was higher in 
F4-2 (71.3 g/100g) compared to F4-3 (1.5 g/100g), F4-4 (3.9 g/100g) and F4-1 (3.9 g/100g). This 
supports the importance of aromatic residues in a peptides’ biological potential, probably 
due to their high steric properties and low lipophilicity. The Tyr amino acid has been 
reported in peptides from milk (e.g., Tyr-Pro-Tyr-Tyr) isolated by a combination of lactic 
acid bacteria fermentation and Flavourzyme® hydrolysis. These peptides are bioavailable 
and exhibit in vitro (90.9 M) and in vivo ACE-I inhibitory activity, the latter in the form of 
reduced hypertension in SHR (15.9 mmHg reduction in systolic blood pressure) [43]. 
F4-2 was also unique in containing Met (0.5 g/100g) and Trp (0.2 g/100g), as well as higher 
concentrations of Ile (3.2 g/100g) and Leu (10.2 g/100g) than the other fractions eluted from 
F4, all of which could have significantly increased its relative ACE-I inhibition activity. This 
would coincide with previous reports of inhibitory activity in peptides with these amino 
acids. The residues Val, Leu and Ile are preferred in the amino terminal position in active 
tripeptides for their low lipophilicity and steric properties or side chain bulk/ molecular size 
[40]. Clearly, the structure of ACE-I inhibitory peptides influences their activity, as shown 
by Cheung et al. [42], who reported that peptides with Tyr at the C-terminus and Ile at the 
N-terminus exhibit highly potent inhibitory activity. In a randomized, double-blind, 
placebo-controlled human study, a significant depressor effect was observed in mild 
essential hypertensive volunteers and Val-Tyr was shown to be one of the predominant 
ACE-I inhibitory peptides involved in this effect [44]. In addition to its high Tyr content, F4-
2 may also be absorbed intact into the human circulatory system and induce a reduction in 
blood pressure. For instance, intravenous and oral administration of Val-Tyr in SHR have 
shown that this di-peptide caused a long-lasting depressor effect. Val-Tyr is known to be 
absorbed intact into the human circulatory system, and studies using cross-mated transgenic 
mice carrying the human renin gene and the human angiotensinogen gene have shown that, 
as a natural ACE-I inhibitory dipeptide, Val-Tyr regulates the enhanced human renin-
angiotensin system and induces a prolonged reduction in blood pressure [45]. 
Of the fractions purified from F5 by preparative RP-HPLC chromatography (Table 3), F5-2, 
F5-3 and F5-4 exhibited ACE-I inhibition that was not different among them (P<0.05), but 
was greater than that of F5-1. The amino acids Arg, Tyr, Met, Ile, Leu, Phe and Lys very 
probably played a key role in providing greater activity to the first three fractions. As 
mentioned above, residues such as Leu and Ile are preferred at the amino terminus of 
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tripeptides with ACE-I inhibitory activity due to their low lipophilicity and steric properties 
or side chain bulk/molecular size values. In addition, Lys and Arg are expected in positions 
adjacent to the amino terminus due to their low electronic properties and high lipophilicity 
and steric property values, while residues such as Phe are preferred at the carboxyl terminus 
due to their low lipophilicity and high steric and electronic property values [41].  
Although the precise substrate specificity is not fully understood, ACE-I appears to prefer 
substrates containing hydrophobic amino acid residues at the three C-terminal positions, 
suggesting that the higher hydrophobic amino acid content in F5-2 (9.1 g/100g), F5-3 (89.8 
g/100g) and F5-4 (34.2 g/100g) versus F5-1 (1.1 g/100g) probably made a substantial 
contribution to their inhibitory potency. This agrees with Wu et al. [40], who state that 
aromatic, positively-charged and hydrophobic amino acids are preferred in active tripeptides. 
Due to substrate specificity differences between the two ACE-I catalytic sites, ACE-I inhibitors 
may inhibit only one site. Moskowitz [46] proposed a model explaining the clinical superiority 
of hydrophobic ACE-I inhibitory drugs relative to hydrophilic ones: all ACE-I inhibitors bind 
to the C-terminal catalytic site, but only hydrophobic ones bind to the occluded N-terminal 
catalytic site and are therefore better at blocking Ang II production. This would also explain 
why hydrophobic ACE-I inhibitors have specific local benefits such as organ damage 
prevention, in addition to reducing blood pressure [46]. The high hydrophobic amino acid 
(particularly aromatic side-chains) content in the F5 may therefore make a substantial 
contribution to its fractions’ ACE inhibitory activity by blocking Ang II production. 
Overall, the highest in vitro ACE-I inhibitory activity (IC50) among the cowpea hydrolysate 
and its derivative fractions was present in the ultrafiltered <1 kDa fraction (0.04 g/mL), 
followed by the RP-HPLC F4-2 fraction (0.4704 g/mL), the gel filtration chromatography 
fraction F4 (14.195 g/mL) and finally the hydrolysate (2634.4 g/mL). Although the IC50 
values for the hydrolysate, F4 and F4-2 fractions were substantially higher than that of the 
F<1 kDa fraction, they are still in the same order of magnitude as values reported for many 
other natural ACE-I inhibitory peptides. Nevertheless, the IC50 values for all the studied V. 
unguiculata derivatives are far higher than that of the synthetic ACE-I inhibitor Captopril® 
(0.0013 g/mL) [32]. The biological potential in the peptides purified from V. unguiculata, 
and the high ACE-I inhibitory activity in the F<1 kDa fraction, reinforce the need for ACE-I 
inhibitory peptides to be rich in hydrophobic amino acids (aromatic or branched chains) and 
peptides rich in Pro. Pro is well-documented as the most favorable amino acid for ACE-I 
binding (most commercial inhibitors include this residue), but it was not present in the 
peptides with potential biological activity that had been purified by G-50 gel filtration 
chromatography and RP-HPLC. 
The studied cowpea V. unguiculata protein hydrolysate has potential applications in the 
development of physiologically functional foods aimed at preventing and/or treating 
hypertension. An added benefit is the balanced amino acid profile of the protein 
hydrolysate and its peptide fractions, which makes them an appropriate protein source in 
human nutrition. It should be considered, however, that the in vitro ACE-I inhibitory 
potencies of peptides do not always correlate with their in vivo antihypertensive activities as 
quantified in SHR. This is because they must be absorbed and transported intact from the 
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intestine to the blood stream (in the case of oral administration) and resist plasma peptidase 
degradation (in the case of oral and intravenous administration) to reach their target sites 
and exert an antihypertensive effect in vivo. Therefore, in vivo research is needed to 
determine to what extent any of the studied ACE-I inhibitory peptides can exercise their 
antihypertensive activity in vivo. 
 
Amino 
acid 
Content (g/100g)*
F4-1 F4-2 F4-3 F4-4 F5-1 F5-2 F5-3 F5-4 
Asx 9.9 ± 0.063 1.2 ± 0.009
0.8 ± 
0.001
12.5 ± 
0.242
2.1 ± 
0.492
1.2 ± 
0.005
2 ± 
0.004 
10.6 ± 
0.731 
Glx 5.1 ± 0.214 1.4 ± 0.048
1.1 ± 
0.006
12.6 ± 
0.329
0 ± 0 
1.5 ± 
0.046
2 ± 
0.071 
14.2 ± 
0.762 
Ser 22.7 ± 0.291
1 ±
0.001
1.2 ± 
0.021
8.4 ± 
0.177
30.5 ± 
0.834
0.9 ± 
0.014
1 ± 
0.014 
8.4 ± 
0.009 
His 8.2 ± 0.677 0.4 ± 0.015
0.3 ± 
0.009
4.1 ± 
0.133
16.3 ± 
0.194
0.3 ± 
0.049
0.4 ± 
0.017 
2.7 ± 
0.957 
Gly 19.6 ± 0.983 1.4 ± 0.008
1.7 ± 
0.031
9.2 ± 
0.226
13.3 ± 
0.159
2.9 ± 
0.017
2 ± 
0.016 
10 ± 
0.057 
Thr 4.3 ± 0.987 0.3 ± 0.005
0.4 ± 
0.018
3.5 ± 
0.066
5.8 ± 
0.069
0.3 ± 
0.048
0.4 ± 
0.024 
2.7 ± 
0.957 
Arg 3.2 ± 0.065 0.8 ± 0.002
0.8 ±
0.01
7.1 ± 
0.151
0 ± 0 
0.2 ± 
0.236
0.6 ± 
0.028 
3 ± 
0.139 
Ala 14.3 ± 0.620 0.4 ± 0.001
0.3 ± 
0.005
3.8 ± 
0.046
1.1 ± 
1.536
0.3 ± 
0.048
0.5 ± 
0.012 
3.4 ± 
0.089 
Pro 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
Tyr 0 ± 0 
71.3 ± 
0.012
1.5 ± 
0.026
3.9 ± 
0.109
0 ± 0 
74.7 ± 
0.280
0.7 ± 
0.109 
4.2 ± 
0.289 
Val 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
Met 0 ± 0 0.5 ± 0.013 0 ± 0 0 ± 0 0 ± 0 
0.6 ± 
0.071
0.1 ± 
0.096 
0.5 ± 
0.039 
Cys 0 ± 0 6.6 ± 0.001
1.3 ± 
0.085
3.6 ± 
0.288
31 ±
0.369
8.8 ± 
0.098
0.9 ± 
0.019 
6.8 ± 
0.070 
Ile 0.4 ± 0.555 3.2 ± 0.041
0.2 ± 
0.020
2.8 ± 
0.059
0 ± 0 
1.6 ± 
0.035
0.5 ± 
0.026 
1.8 ± 
0.032 
Leu 9.3 ± 0.217
10.2 ± 
0.006
0.3 ± 
0.008
4.7 ± 
0.024
0 ± 0 
3.1 ± 
0.066
0.8 ± 
0.093 
6.1 ± 
0.896 
Phe 0 ± 0 0.8 ± 0.003
89.6 ± 
0.230 
20 ±
 
0.778
0 ± 0 
3.5 ± 
0.765 
87.9 ± 
0.234 
22.4 ± 
0.304 
Lys 
3± 
0.532
0.3 ± 0.007
0.3 ± 
0.008
3.8 ± 
0.068
0 ± 0 
0.2 ± 
0.009
0.3 ± 
0.002 
2.4 ± 
0.073 
Trp 0 ± 0 0.2 ± 0.040 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
Table 3. Amino acid contents of fractions from the F4 and F5 gel filtration chromatography fraction 
purified by preparative RP-HPLC C-18 chromatography.  
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4. Conclusions 
After modification by Alcalase®, Flavourzyme® and pepsin-pancreatin cowpea V. 
unguiculata proteins proved to be a source of bioactive peptides with ACE-I inhibitory and 
antioxidant activity. Fractionation of V. unguiculata enzymatic hydrolysates by 
ultrafiltration enhanced their ACE-I inhibitory and antioxidant activity in all the resulting 
peptides, although the <1 kDa fraction of the Flavourzyme hydrolysate had the highest 
overall biological activity. Further purification of this fraction by gel filtration 
chromatography and RP-HPLC produced fractions with different activities, all of which 
were much higher than the source hydrolysate. Separation of protein hydrolysates by 
molecular weight and hydrophobicity clearly enhanced peptide ACE-I inhibitory activity, 
particularly purification by ultrafiltration and chromatography. The highest biological 
potential among the purified peptides was observed in the ultrafiltered <1 kDa fraction, 
which supports the importance of high hydrophobic amino acid and proline content in 
ACE-I inhibitory peptides. These results highlight the promise of controlled protein 
hydrolysis with a fungal protease complex to isolate bioactive peptides from cowpea V. 
unguiculata proteins, which can then be further purified and/or used as an ingredient in 
functional foods designed for specific diets. 
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